MRI contrast agents
    1.
    发明授权
    MRI contrast agents 失效
    MRI造影剂

    公开(公告)号:US07368099B2

    公开(公告)日:2008-05-06

    申请号:US10546964

    申请日:2004-02-03

    IPC分类号: A61B5/055 A61K49/00

    CPC分类号: A61K49/085 A61K49/10

    摘要: An MRI contrast agent enables direct detection and imaging of exfoliated vascular endothelial sites. The MRI contrast agent includes an imaging unit which contains an unpaired electron-carrying atom and/or molecule and is capable of amplifying or reducing MRI signals, and a detection unit which is bonded to the imaging unit and is capable of selectively recognizing exfoliated vascular endothelial sites and binding thereto. The detection unit is exemplified by one having a chemical structure expressed by the following formula (I), wherein at least one of R1-R11 is, for example, a sulfonic acid group, and X is, for example, a phenyl group which may be substituted:

    摘要翻译: MRI造影剂能够直接检测和成像脱落的血管内皮部位。 MRI造影剂包括成像单元,其包含不成对的电子携带原子和/或分子并且能够放大或减少MRI信号;以及检测单元,其结合到成像单元并且能够选择性地识别脱落的血管内皮 网站和绑定。 检测单元由具有由下式(I)表示的化学结构的检测单元举例说明,其中R 1〜R 11中的至少一个为例如 磺酸基,X是例如可以被取代的苯基:

    Contrast medium for mri
    2.
    发明申请
    Contrast medium for mri 失效
    mri的对比介质

    公开(公告)号:US20060153773A1

    公开(公告)日:2006-07-13

    申请号:US10546964

    申请日:2004-02-03

    IPC分类号: A61B5/055

    CPC分类号: A61K49/085 A61K49/10

    摘要: Disclosed is an MRI contrast agent which enables direct detection and imaging of exfoliated vascular endothelial sites. The MRI contrast agent comprises an imaging unit which contains an unpaired electron-carrying atom and/or molecule and is capable of amplifying or reducing MRI signals, and a detection unit which is bonded to said imaging unit and is capable of selectively recognizing exfoliated vascular endothelial sites and binding thereto. The detection unit is exemplified by one having a chemical structure expressed by the following formula (I), wherein at least one of R1-R11 is, for example, sulfonic acid group, and X is, for example, a phenyl group which may be substituted:

    摘要翻译: 公开了一种MRI造影剂,其能够直接检测和成像脱落的血管内皮部位。 MRI造影剂包括成像单元,其包含不成对的电子携带原子和/或分子并且能够放大或减少MRI信号;以及检测单元,其结合到所述成像单元并且能够选择性地识别脱落的血管内皮 网站和绑定。 检测单元由具有由下式(I)表示的化学结构的检测单元举例说明,其中R 1〜R 11中的至少一个为例如磺酸基 酸基,X是例如可以被取代的苯基:

    Ultrasound treatment device and control method thereof

    公开(公告)号:US10413756B2

    公开(公告)日:2019-09-17

    申请号:US13990233

    申请日:2010-12-09

    摘要: When a user designates a treatment range on a diagnostic image, a switch (12) selects a transmitter for treatment (16). Ultrasound with intensity for treatment is thereby transmitted from a probe (10) to the inside of an organism. When the treatment operation continues for a prescribed time, a control unit (18) controls the switch (12) to select a transmitter for diagnosis (14). The probe (10) thereby emits an ultrasound beam for diagnosis, senses an echo thereof, generates a diagnostic image, and carries out an inspection of a positional shift of the site to be treated. In the inspection, the control unit (18) compares the diagnostic image with a reference image, and if a significant difference is detected therebetween, determines that a shift has occurred, issues an alarm, and urges the user to correct the positional shift. It is possible to resume the treatment when the positional shift has been corrected.

    Method of determining dose and administration of statin
    4.
    发明授权
    Method of determining dose and administration of statin 有权
    测定他汀类药物剂量和给药方法

    公开(公告)号:US08759012B2

    公开(公告)日:2014-06-24

    申请号:US13316246

    申请日:2011-12-09

    摘要: The object of the present invention is to provide a method of determining the dose and/or administration of statins to a patient suffering from a cardiovascular disease.The object is achieved by the method of determining the dose and/or administration of statins to a patient suffering from a cardiovascular disease comprising Step (1) of measuring the intracellular SmgGDS expression level of a patient suffering from a cardiovascular disease before and after administration of statin; and Step (2) of determining the type and/or the dose of statin for the patient in reference to the SmgGDS expression level measured in the Step (1).

    摘要翻译: 本发明的目的是提供一种确定患有心血管疾病的患者的他汀类药物的剂量和/或给药方法。 该目的通过确定对患有心血管疾病的患者的剂量和/或给药的方法来实现,所述方法包括步骤(1):测量患有心血管疾病的患者在施用前后的SmgGDS表达水平 他汀类 和步骤(2),其参考步骤(1)中测量的SmgGDS表达水平来确定患者的他汀类的类型和/或剂量。

    ULTRASOUND TREATMENT DEVICE AND CONTROL METHOD THEREOF
    5.
    发明申请
    ULTRASOUND TREATMENT DEVICE AND CONTROL METHOD THEREOF 审中-公开
    超声处理装置及其控制方法

    公开(公告)号:US20130261508A1

    公开(公告)日:2013-10-03

    申请号:US13990233

    申请日:2010-12-09

    IPC分类号: A61N7/00

    摘要: When a user designates a treatment range on a diagnostic image, a switch (12) selects a transmitter for treatment (16). Ultrasound with intensity for treatment is thereby transmitted from a probe (10) to the inside of an organism. When the treatment operation continues for a prescribed time, a control unit (18) controls the switch (12) to select a transmitter for diagnosis (14). The probe (10) thereby emits an ultrasound beam for diagnosis, senses an echo thereof, generates a diagnostic image, and carries out an inspection of a positional shift of the site to be treated. In the inspection, the control unit (18) compares the diagnostic image with a reference image, and if a significant difference is detected therebetween, determines that a shift has occurred, issues an alarm, and urges the user to correct the positional shift. It is possible to resume the treatment when the positional shift has been corrected.

    摘要翻译: 当用户在诊断图像上指定治疗范围时,开关(12)选择用于治疗的发射器(16)。 因此,具有治疗强度的超声从探针(10)传播到生物体的内部。 当治疗操作持续规定时间时,控制单元(18)控制开关(12)选择用于诊断的发射器(14)。 因此,探针(10)发射用于诊断的超声波束,感测其回波,产生诊断图像,并对待处理部位的位置偏移进行检查。 在检查中,控制单元(18)将诊断图像与参考图像进行比较,并且如果在其间检测到显着差异,则确定发生了移位,发出报警,并且敦促用户校正位置偏移。 当位置偏移被校正时,可以恢复处理。

    Therapeutic Agent for Vasospasm Accompanying Bypass Operation
    6.
    发明申请
    Therapeutic Agent for Vasospasm Accompanying Bypass Operation 审中-公开
    伴随旁路手术的血管痉挛治疗剂

    公开(公告)号:US20080242660A1

    公开(公告)日:2008-10-02

    申请号:US10597357

    申请日:2005-01-27

    申请人: Hiroaki Shimokawa

    发明人: Hiroaki Shimokawa

    IPC分类号: A61K31/5513 A61P9/00

    CPC分类号: C07D401/12 A61K31/4375

    摘要: An agent and composition for the prevention of and/or treatment for vasospasm accompanying a bypass operation, which contains as an active ingredient either a compound represented by the following general formula (I) or an acid addition salt or hydrate thereof. R1 represents a hydrogen atom or a hydroxyl group.

    摘要翻译: 用于预防和/或治疗伴随旁路手术的血管痉挛的药剂和组合物,其包含作为活性成分的由以下通式(I)表示的化合物或其酸加成盐或其水合物。 R 1表示氢原子或羟基。

    Optical fiber and an underwater shockwave generating device employing the same
    7.
    发明授权
    Optical fiber and an underwater shockwave generating device employing the same 有权
    光纤和采用该光纤的水下冲击波发生装置

    公开(公告)号:US09433466B2

    公开(公告)日:2016-09-06

    申请号:US13880530

    申请日:2011-07-27

    摘要: An optical fiber is provided which has good laser beam condensation efficiency and is highly resilient, and a shockwave generating device employing same. An optical fiber is employed in an underwater shockwave generating device which projects a laser beam underwater and generates an underwater shockwave. The optical fiber includes a main body part, and a laser convergence part that is disposed upon a leading end thereof. The laser convergence part is configured so as to exhibit an approximately frustum shape wherein the diameter of the leading end is narrower than the diameter of the base end, and such that an interior angle with respect to a radial direction of a lateral face of an axial cross-section gradually decreases toward the front thereof.

    摘要翻译: 提供了具有良好的激光束冷凝效率和高弹性的光纤,以及采用该光纤的冲击波产生装置。 在水下冲击波产生装置中采用光纤,其将水下的激光束投射并产生水下冲击波。 光纤包括主体部分和设置在其前端上的激光会聚部分。 激光会聚部被构造为呈现大致截头体形状,其中前端的直径比基端的直径窄,并且使得相对于轴向的侧面的径向方向的内角 横截面朝向其前方逐渐减小。

    OPTICAL FIBER AND AN UNDERWATER SHOCKWAVE GENERATING DEVICE EMPLOYING THE SAME
    8.
    发明申请
    OPTICAL FIBER AND AN UNDERWATER SHOCKWAVE GENERATING DEVICE EMPLOYING THE SAME 有权
    光纤和水下冲击产生装置

    公开(公告)号:US20130274726A1

    公开(公告)日:2013-10-17

    申请号:US13880530

    申请日:2011-07-27

    IPC分类号: A61B18/22 G02B6/26

    摘要: Provided are an optical fiber which has good laser beam condensation efficiency and is highly resilient, and a shockwave generating device employing same. An optical fiber (11) is employed in an underwater shockwave generating device (10) which projects a laser beam underwater and generates an underwater shockwave. The optical fiber (11) comprises: a main body part (16); and a laser convergence part (17) which is disposed upon a leading end thereof. The laser convergence part (17) is configured so as to exhibit an approximately frustum shape wherein the diameter of the leading end (18a) is narrower than the diameter of the base end (18b), and such that an interior angle θ with respect to a radial direction of a lateral face, of an axial cross-section gradually decreases toward the front thereof.

    摘要翻译: 提供了具有良好的激光束冷凝效率和高弹性的光纤,以及采用该光纤的冲击波产生装置。 在水下冲击波产生装置(10)中使用光纤(11),其将水下的激光束投射并产生水下冲击波。 光纤(11)包括:主体部分(16); 以及设置在其前端的激光会聚部(17)。 激光会聚部分(17)被构造成呈现大致截头锥形状,其中前端(18a)的直径比基端(18b)的直径窄,并且使得相对于 轴向横截面的侧面的径向方向朝向其前方逐渐减小。

    METHOD OF DETERMINING DOSE AND ADMINISTRATION OF STATIN
    9.
    发明申请
    METHOD OF DETERMINING DOSE AND ADMINISTRATION OF STATIN 有权
    测定剂量和管理方法

    公开(公告)号:US20130065226A1

    公开(公告)日:2013-03-14

    申请号:US13316246

    申请日:2011-12-09

    IPC分类号: G01N33/573 C12Q1/68

    摘要: The object of the present invention is to provide a method of determining the dose and/or administration of statins to a patient suffering from a cardiovascular disease.The object is achieved by the method of determining the dose and/or administration of statins to a patient suffering from a cardiovascular disease comprising Step (1) of measuring the intracellular SmgGDS expression level of a patient suffering from a cardiovascular disease before and after administration of statin; and Step (2) of determining the type and/or the dose of statin for the patient in reference to the SmgGDS expression level measured in the Step (1).

    摘要翻译: 本发明的目的是提供一种确定患有心血管疾病的患者的他汀类药物的剂量和/或给药方法。 该目的通过确定对患有心血管疾病的患者的剂量和/或给药的方法来实现,所述方法包括步骤(1):测量患有心血管疾病的患者在施用前后的SmgGDS表达水平 他汀类 和步骤(2),其参考步骤(1)中测量的SmgGDS表达水平来确定患者的他汀类的类型和/或剂量。